Indaptus Therapeutics announces resignation of two directors and COO; COO to serve as consultant

Indaptus Therapeutics, Inc.

David E. Lazar and Avraham Ben-Tzvi resigned from all director positions and committees effective June 5, 2026.
Walt A. Linscott resigned as COO effective June 1, 2026, and will serve as consultant under a consulting agreement.
Resignations were not due to any disagreement with the company's operations, policies, or practices.
No replacements for directors or COO were announced; CEO Junyi Dai remains in place.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David E. Lazar

Director

INDP · Indaptus Therapeutics, Inc.

Effective: 2026-06-05
Filed: June 5, 2026, 4:30 PM ET

Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Company ”).

Departed

Walt A. Linscott

Chief Operating Officer

INDP · Indaptus Therapeutics, Inc.

Effective: 2026-06-01
Filed: June 5, 2026, 4:30 PM ET

Effective as of June 1, 2026, Mr. Walt A. Linscott, Esq. resigned as the Chief Operating Officer of the Company, and, pursuant to a consulting agreement with the Company dated June 1, 2026, will serve as a consultant for the Company.

Departed

Avraham Ben-Tzvi

Director

INDP · Indaptus Therapeutics, Inc.

Effective: 2026-06-05
Filed: June 5, 2026, 4:30 PM ET

Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Company ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David E. Lazar resigned as Director at Indaptus Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Company ”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Walt A. Linscott resigned as Chief Operating Officer at Indaptus Therapeutics, Inc..

Action: resigned
Role: Chief Operating Officer

Exact text from the filing

Effective as of June 1, 2026, Mr. Walt A. Linscott, Esq. resigned as the Chief Operating Officer of the Company, and, pursuant to a consulting agreement with the Company dated June 1, 2026, will serve as a consultant for the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Avraham Ben-Tzvi resigned as Director at Indaptus Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Company ”).

View on SEC.gov

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-027499

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.